Radiofrequency ablation

Compass Group Announces Launch of Interventional Pain Management Platform with Anchor Investment in Leading Memphis Practice

Retrieved on: 
Tuesday, September 13, 2022

Compass Group Equity Partners, a St. Louis-based private equity firm, today announced a strategic partnership with Mays & Schnapp Neurospine and Pain (Mays & Schnapp), a Memphis-based interventional pain management practice serving patients in Tennessee and Mississippi.

Key Points: 
  • Compass Group Equity Partners, a St. Louis-based private equity firm, today announced a strategic partnership with Mays & Schnapp Neurospine and Pain (Mays & Schnapp), a Memphis-based interventional pain management practice serving patients in Tennessee and Mississippi.
  • Were thrilled about this partnership with Dr. Moacir Schnapp, Eric Schnapp, and the rest of the team, said John Hubert, Vice President at Compass Group.
  • The platform is seeking add-on interventional pain management physicians and practices that are committed to providing best-in-class care to patients.
  • Today, the practice offers a full suite of innovative interventional pain management services while focusing on minimally invasive techniques.

S4 Medical Meets Primary Endpoint in Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF Study)

Retrieved on: 
Monday, September 12, 2022

CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF) Study due to successful achievement of the primary endpoint.

Key Points: 
  • CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF) Study due to successful achievement of the primary endpoint.
  • "Completion of the IDE study and meeting our primary endpoint was a massive milestone for S4," says William Fuller, CEO and co-founder of S4 Medical.
  • About S4 Medical Corp: S4 Medical Corp is a medical device company focused on innovative solutions for cardiac procedures.
  • The company's initial product is a simple, yet comprehensive solution intended at reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation.

Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH

Retrieved on: 
Wednesday, September 7, 2022

The Guidelines will provide physicians and patient families with the best recommendations and the latest evidence for the diagnosis and treatment of PAH worldwide.

Key Points: 
  • The Guidelines will provide physicians and patient families with the best recommendations and the latest evidence for the diagnosis and treatment of PAH worldwide.
  • PADN is a vascular interventional ablation technology that uses radiofrequency ablation to block pulmonary intima sympathetic nerves and reduce pulmonary artery pressure to delay disease progression.
  • The Guidelines include an introduction and analysis of the PADN technique as part of the treatment for PAH.
  • The single-blind, randomized, sham-operated controlled clinical study is designed to evaluate the safety and efficacy of PADN surgery for PAH.

Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study

Retrieved on: 
Wednesday, September 7, 2022

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of Chronic Low Back Pain (CLBP) and related disability caused by Degenerative Disc Disease (DDD), today announced the first patient treated in a Phase 3 clinical study of SB-01 For Injection (SB-01). The SB-01 Phase 3 study is known as the MODEL Study (Moderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine). SB-01 is the first intradiscal pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD. 

Key Points: 
  • The SB-01 Phase 3 study is known as the MODEL Study (Moderate Severe Degenerative Disc Disease Evaluation of the Lumbar Spine).
  • SB-01 is the first intradiscal pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD.
  • The patient was treated at Conquest Research in Winter Park, FL where Dr. Malisa Agard is the Principal Investigator.
  • The Phase 3 study of SB-01 is being conducted at 30 investigational sites across the US, enrolling up to 400 patients (Clinicaltrials.gov: NCT05516992 ).

CHOC Hospital is first in Southern California to earn national verification from American College of Surgeons

Retrieved on: 
Wednesday, August 17, 2022

ORANGE, Calif., Aug. 17, 2022 /PRNewswire/ -- CHOC Hospital has been granted Level 1 Children's Surgical Verification by the American College of Surgeons (ACS). This notable achievement acknowledges CHOC's steadfast commitment to quality improvement and patient safety efforts for children requiring surgical services. CHOC is the first hospital to earn this distinction in Southern California and one of only four in the state.

Key Points: 
  • ORANGE, Calif., Aug. 17, 2022 /PRNewswire/ -- CHOC Hospital has been granted Level 1 Children's Surgical Verification by the American College of Surgeons (ACS).
  • This notable achievement acknowledges CHOC's steadfast commitment to quality improvement and patient safety efforts for children requiring surgical services.
  • CHOC is the first hospital to earn this distinction in Southern California and one of only four in the state.
  • The application process for verification is followed by an extensive site visit by an ACS team of surveyors that include experienced pediatric surgeons, anesthesiologists, and nurses.

United Kingdom Renal Denervation Market Report 2022-2027: Rising Numbers Suffering with Hypertension Augmenting Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022

United Kingdom renal denervation market may flourish with an impressive CAGR during the forecast period of 2023-2027, on the backbone of increasing number of patients suffering from hypertension.

Key Points: 
  • United Kingdom renal denervation market may flourish with an impressive CAGR during the forecast period of 2023-2027, on the backbone of increasing number of patients suffering from hypertension.
  • Rising instances of high blood pressure among the population drives the growth of the United Kingdom renal denervation market in the upcoming five years.
  • Growing instances of therapy resistant hypertension may also be considered as a key growth factor for the United Kingdom renal denervation market in the next five years.
  • In this report, United Kingdom renal denervation market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    United Kingdom Renal Denervation Market, By Technology:

Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter

Retrieved on: 
Monday, July 11, 2022

The MAGiC catheter is a robotically navigated magnetic interventional ablation catheter for minimally invasive cardiac ablation procedures.

Key Points: 
  • The MAGiC catheter is a robotically navigated magnetic interventional ablation catheter for minimally invasive cardiac ablation procedures.
  • Used in conjunction with Stereotaxis robotic systems, the MAGiC catheter is designed to provide unparalleled catheter precision, stability and flexibility when diagnosing and treating cardiac arrhythmias.
  • CE Mark submission of the MAGiC catheter reflects the culmination of an extensive design, development, manufacturing and testing effort.
  • Stereotaxis anticipates making the MAGiC catheter commercially available for robotic electrophysiology practices in Europe following receipt of CE Mark as early as years end.

EmergeOrtho--Triangle Region Welcomes Deitra Williams-Toone, MD

Retrieved on: 
Wednesday, June 22, 2022

DURHAM, N.C., June 22, 2022 /PRNewswire/ -- EmergeOrthoTriangle Region welcomes Dr. Deitra Williams-Toone to the interventional pain management team, with subspecialties in radiofrequency ablation, spinal cord stimulation, and anesthesiology.

Key Points: 
  • DURHAM, N.C., June 22, 2022 /PRNewswire/ -- EmergeOrthoTriangle Region welcomes Dr. Deitra Williams-Toone to the interventional pain management team, with subspecialties in radiofrequency ablation, spinal cord stimulation, and anesthesiology.
  • Deitra Williams-Toone, MD is a native North Carolinian and proud Tar Heel.
  • "Managing patient pain and providing healthy alternatives to combat chronic pain is something I really prioritize," Deitra Williams-Toone, MD says.
  • "We are excited to welcome Dr. Deitra Williams-Toone to EmergeOrtho pain management department," says Eugenia Zimmerman, M.D .

Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer

Retrieved on: 
Tuesday, June 21, 2022

PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled “Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma,” establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).

Key Points: 
  • The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin.
  • The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization.
  • Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study.
  • A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.

Global Renal Denervation Market Report (2022 to 2028) - Size, Share & Industry Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 15, 2022

The "Global Renal Denervation Market Size, Share & Industry Trends Analysis Report By Technology (Radiofrequency, Ultrasound, and Micro-Infusion), By End User, By Product Type By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Denervation Market Size, Share & Industry Trends Analysis Report By Technology (Radiofrequency, Ultrasound, and Micro-Infusion), By End User, By Product Type By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Renal Denervation Market size is expected to reach $1.4 billion by 2028, rising at a market growth of 36.4% CAGR during the forecast period.
  • Ultrasound ablates nerves in the renal artery wall, interrupting nerve impulse transmission and decreasing blood pressure with ultrasound-based renal denervation devices.
  • Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems.